Navigation Links
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Date:3/17/2008

NASDAQ: CRME TSX: COM

VANCOUVER, March 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced positive interim clinical results from its 90-day Phase 2b study of vernakalant (oral). The interim analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the interim analysis also suggests that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied during the dosing period under analysis.

A Kaplan-Meier analysis of the 446 patients included in the interim dataset demonstrated a significant efficacy benefit for the 500mg dosing group as compared to placebo (two-sided, p<0.05). Median time to recurrence of atrial fibrillation was greater than 90 days for the 500mg dosing group, compared to 39 days for the placebo group. 52% of patients in the 500mg dosing group (n=110) completed the study in normal heart rhythm compared to 39% of patients receiving placebo (n=118). The interim efficacy analysis for the 150mg (n=110) and 300mg (n=108) dosing groups had not achieved statistical significance at the interim timepoint.

"This larger-scale, longer-term study of vernakalant (oral) was designed to find the appropriate dose to take into Phase 3, and to confirm our assumptions regarding safety," said Dr. Charles Fisher, Executive Vice President and Chief Medical Officer of Cardiome. "While the study is ongoing and we must await the final data before drawing conclusions, these statistically significant and clinically significant efficacy results as well as the attractive safety profile observed in this interim analysis strongly support our belief in the exciting potential of vernakalant (oral) as a therapy for atrial fibrillation."

The safety data for all dosing groups suggests that vernakalant (oral) was well-tolerated within the interim safety populatio
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. Cardiome to Hold Investor Update Call
3. Cardiome Updates Guidance
4. Cardiome Initiates Phase 1 Study for GED-aPC
5. Cardiome To Release Third Quarter Results
6. Cardiome to Present at CIBC Conference
7. Cardiome to Present at ThinkEquity Conference
8. Cardiome to Present at Bear Stearns Conference
9. Weight Watchers Announces Election of Kim Roy to Board of Directors
10. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 The noted Toronto ... Facial Surgery was recently featured in the January/February 2015 ... magazine, Dr. David Ellis was featured in an article ... various cosmetic enhancements that Kim Cattrall has possibly undergone ... “Her forehead is smooth without horizontal lines or frown ...
(Date:2/28/2015)... ” was featured on NewsWatch as part of its monthly ... coolest technology products and services available to consumers. Scott Steinberg, ... the review and shared with viewers how they provide a ... low battery and no way to charge a phone or ... basis. Even when a person does have a charger, sitting ...
(Date:2/28/2015)... 28, 2015 The World Scout League ... materials to potential EMTs and firefighters, recently announced its ... a way to raise charitable donations for age-related research. ... Columbia, will be held on March 29, 2015; registration ... begin at 3:30 p.m. , To participate in ...
(Date:2/27/2015)... 27, 2015 Hispanics develop alcoholic liver ... four and 12 years earlier than Whites/Caucasians or African ... Health System. , While previous research indicated that Hispanics ... the new study -- published online in the journal ... be the first to pinpoint racial and ethnic disparities ...
(Date:2/27/2015)... A new study published in the ... who cycle on a regular basis and prostate cancer. While ... that the more hours per week a man spends cycling, ... to an increased importance on prostate cancer screening methods. , ... more closely at patents’ risk factors for developing prostate cancer,” ...
Breaking Medicine News(10 mins):Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3
... ... Drexel University in November , ... Philadelphia, PA (PRWEB) November 11, 2009 -- Drexel University Online ... for demonstrating its commitment to training and development through various forms of eLearning to ...
... ... services, Ms. McKenna and the Beyond the Box team can assist seniors and their loved ... ... Washington, DC based relocation and design firm, Beyond the Box , is pleased to ...
... ... ECG core lab market with largest number of highly automated QT(sm) studies. , ... Rochester, NY (PRWEB) November ... services and QT analysis, announced today that a top five pharmaceutical company has awarded ...
... of workplace exposure to Bisphenol-A may increase the risk of ... study appearing online in the journal Human Reproduction, ... study examined 634 workers in factories in China, comparing workers ... in factories where no BPA was present. The study found ...
... Emory University Rollins School of Public Health researchers ... at the American Public Health Association,s annual meeting in ... employees participating in a large-scale worksite wellness program. ... are highlighted below. Does faith affect how ...
... 10 Centene Corporation (NYSE: CNC ) announced ... Massachusetts Inc.(TM) (CeltiCare), and representatives from the Health Connector, ... affordable healthcare for all Massachusetts consumers. , In ... on schedule and on a voluntary basis. CeltiCare ...
Cached Medicine News:Health News:Catholic Health East Named 2009 National Distance Learning Week Award Recipient 2Health News:Catholic Health East Named 2009 National Distance Learning Week Award Recipient 3Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 2Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 3Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 4Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 5Health News:Worksite wellness programs may reduce employee absenteeism 2Health News:CeltiCare Confirms Timetable For Launch of Products With Massachusetts Health Connector 2
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015   Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Disorders™ (NORD™), the European Organisation for Rare Diseases™ ... the world in observing Rare Disease Day. ... year, patient organizations, industry, and other participants conduct ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... ease of use with high software ... image guided system for neurosurgery that ... needs. With a 50% usage rate ... than 500 physicians, VectorVision Cranial is ...
... microsurgical system delivers on the promise ... For the latest advancement in fluidics ... & Lomb Surgical offers CONCENTRIX™ Fluidics ... to provide both flow and vacuum ...
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
Medicine Products: